Detalhe da pesquisa
1.
How I treat multiple myeloma in geriatric patients.
Blood
; 143(3): 224-232, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36693134
2.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
3.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
4.
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.
Haematologica
; 109(2): 604-616, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584290
5.
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Hematol Oncol
; 42(2): e3258, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402467
6.
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Br J Haematol
; 201(6): 1103-1115, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974007
7.
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.
Oncologist
; 28(5): e263-e269, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37002943
8.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
9.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood
; 138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827114
10.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
11.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
12.
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica
; 108(5): 1374-1384, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36172814
13.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
14.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet
; 397(10292): 2361-2371, 2021 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097854
15.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
16.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
17.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Hematol Oncol
; 40(5): 1020-1029, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653225
18.
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Eur J Haematol
; 109(5): 504-512, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871357
19.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
20.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288